Relmada cut to neutral by Mizuho on Phase 3 study failure

RLMD Stock  USD 0.37  0.05  12.60%   
About 55% of Relmada Therapeutics' shareholders are presently thinking to get in. The analysis of overall sentiment of trading Relmada Therapeutics stock suggests that some investors are interested at this time. The current market sentiment, together with Relmada Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Relmada Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
Mizuho has downgraded Relmada Therapeutics to neutral on the apparent demise of its drug candidate REL-1017 for major depressive disorder. Read more here.

Read at seekingalpha.com
seekingalpha News
  

Relmada Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Relmada Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Relmada Therapeutics Fundamental Analysis

We analyze Relmada Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Relmada Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Relmada Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Earnings Per Share

Earnings Per Share Comparative Analysis

Relmada Therapeutics is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.

Relmada Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Relmada Therapeutics stock to make a market-neutral strategy. Peer analysis of Relmada Therapeutics could also be used in its relative valuation, which is a method of valuing Relmada Therapeutics by comparing valuation metrics with similar companies.

Peers

Relmada Therapeutics Related Equities

AMPHAmphastar   3.08   
0%
100.0%
EBSEmergent Biosolutions   2.68   
0%
87.0%
ALVOAlvotech   1.04   
0%
33.0%
BHCBausch Health   0.92   
0%
29.0%
HLNHaleon Plc   0.83   
0%
26.0%
ITCIIntracellular   0.05   
1.0%
0%
CTLTCatalent   0.22   
7.0%
0%
TAKTakeda Pharmaceutical   0.37   
12.0%
0%
NBIXNeurocrine Biosciences   0.62   
20.0%
0%
TEVATeva Pharma   1.66   
53.0%
0%

Complementary Tools for Relmada Stock analysis

When running Relmada Therapeutics' price analysis, check to measure Relmada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relmada Therapeutics is operating at the current time. Most of Relmada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relmada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relmada Therapeutics' price. Additionally, you may evaluate how the addition of Relmada Therapeutics to your portfolios can decrease your overall portfolio volatility.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Equity Valuation
Check real value of public entities based on technical and fundamental data
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets